Toyota Kirloskar Motor (TKM), the Indian subsidiary of Toyota, will showcase its much-hyped Etios Cross at the upcoming Auto Expo 2014 in New Delhi.The vehicle, which was unveiled in Brazil and Argentina in November, has been spotted testing on Indian roads for quite some time. The car – a restyled version of Toyota Etios Liva hatchback – will come powered by the same the 1.4 liter, 68 bhp diesel engine or the 1.5 liter, 89 bhp petrol engine. According to reports, the car is based on the Etios Liva though the exterior flaunts an overhauled look.The Etios Cross looks sportier than the Etios Liva and is expected to come with features like a new front bumper and diamond cut 10-spoke alloy wheels. When launched, the vehicle will take on the likes of Volkswagen Polo Cross and Fiat Punto Cross.Meanwhile, Toyota has launched two new variants of its premium hatchback Etios Liva, dubbed VD and VD SP. Previously Etios was available in four variants – JD, GD, GD Safety Package (SP) and TRD Sportivo.Toyota Etios Liva VD comes at a price of Rs. 6.72 lakh, while the VD SP variant is priced at Rs. 7.12 lakh. The engine specifications of both models remain the same as 1.4-litre motor which can churn a power of 67 bhp with peak torque of 170 Nm.The Auto Expo 2014 is speculated to see the unveiling of around 20 new cars. Auto majors like Maruti Suzuki, Hyundai, Volkswagen, Ford, Audi, Chevrolet, Nissan, BMW, Honda, Toyota, Jaguar Land Rover, Volvo and Mercedes-Benz are all said to be getting ready to dazzle at the event.
Shares of Dr Reddy’s Laboratories (DRL) plunged by almost 3.50 percent on the BSE on Tuesday after the company reported lower-than-expected revenues and net profit for the third quarter ended 31 December, 2015. The Hyderabad-based company reported consolidated net profit of Rs 579.20 crore for the third quarter, a marginal increase from Rs 574.50 crore in the year-ago period. The company’s net profit was hit due to a foreign exchange loss of Rs 63.70 crore on account of “increasing risk of currency devaluation” in Venezuela, the company said in a regulatory filing to the BSE. Moreover, Dr Reddy’s Lab said that the impact could spill over to its March quarter earnings as well. Consolidated revenues of the company stood at Rs 3,967.90 crore, up 3.24 percent from Rs 3,843.10 crore.An average of estimates by analysts in a CNBC-TV18 poll had pegged the net profit at Rs 648.34 crore and revenues at Rs 4,007 crore. The company’s domestic sales and US sales were likely to record growth but the one-time write off due to devaluation of stocks in Venezuela and Russia was expected to hit net profit.Brokerage firm Angel Broking had estimated net profit of Rs 746 crore and revenues to come at Rs 4,420 crore.The company said it is evaluating its current arrangements with the Venezulean government to facilitate the payments related to import of pharma products at the CENCOEX preferential rate 6.3 VEF per US dollar. “The company will fully consider all the developments facts and circumstances during the three months ending 31 March, 2016, in evaluating the appropriate translate rate to be applied. If the facts and circumstances support a conclusion that the CENCOEX rate is no longer appropriate, it could have a significant impact on the consolidated financial statements of the company,” it said. In its analysis of the results, Angel Broking said, “The lower than expected sales performance is on back of the Emerging market (Rs 639.9 crore) which dipped by 28.0% YoY. Russia with sales of Rs 310 crore declined by 21% YoY, on back of deprecation of rubble.””The key regions — USA (Rs 1941.7 crore) posted a robust growth of 18% YoY, Europe (Rs 194 crore) posted a YoY growth of 14% and India did sales of Rs 581crore, a YoY growth of 34% (aided by the UCB acquired brands). Overall generic segment posted a sales growth of 7% YoY, while PSAI segment posted a sales de-growth of 17%,” the brokerage said. Shares of Dr Reddy’s Lab were trading at Rs 2,966.50 at around 2.20 pm, down 3.39 percent from its Monday close.
SM SirajuddoulaThe case filed against SM Sirajuddoula, principal of Sonagazi Islamia Senior Fazil Madrasa for sexually harassing his student Nusrat Jahan Rafi before burning her to death, was shifted to Women and Children Repression Prevention Tribunal on Thursday.Feni senior judicial magistrate Zakir Hossain shifted the case fixing 9 July for the next hearing.On Wednesday, the court took cognisance of charges brought against SM Sirajuddoula after Police Bureau of Investigation (PBI) submitted the charge-sheet.The PBI submitted the 271-page charge-sheet 98 days into the sexual harassment of the madrasa girl. A total of 29 people were made witnesses in the case.Meanwhile, night guard M Mostafa of the madrasa testified before the Women and Children Repression Prevention Tribunal on Thursday in murder case filed over the killing of Nusrat.Tribunal judge Mamunur Rashid fixed 7 July for the next hearing.On 27 March, Sirajuddoula sexually harassed Nusrat in his office. Her mother filed the case against the principal the following day.On 6 April, Nusrat was set afire at an examination centre allegedly by people loyal to the principal after he was arrested and subsequently suspended following the filing of the case.She lost her battle for life on 10 April at Dhaka Medical College Hospital in the capital.